Mifepristone treatment of olanzapine-induced weight gain in healthy men

Advances in Therapy

Volumn 26, Issue 10, 2009, Pages 959-969

  Gross, Coleman ^a   Blasey, Christine M ^a   Roe, Robert L ^a   Allen, Kate ^a   Block, Thaddeus S ^a   Belanoff, Joseph K ^a  

^a Corcept Therapeutics ^*  (United States)

Author keywords

Antipsychotic; Mifepristone; Olanzapine; Weight gain

Indexed keywords

MIFEPRISTONE; OLANZAPINE; PLACEBO;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; BODY WEIGHT DISORDER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHTS AND MEASURES; DOUBLE-BLIND METHOD; HORMONE ANTAGONISTS; HUMANS; INSULIN; LIPIDS; MALE; MIFEPRISTONE; WEIGHT GAIN; YOUNG ADULT;

EID: 73949134203     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-009-0070-1     Document Type: Article

References (38)

1. J.M. Davis N. Chen I.D. Glick 2003 A meta-analysis of the efficacy of second-generation antipsychotics Arch Gen Psychiatry 60 553 564 10.1001/archpsyc.60.6.553 1:CAS:528:DC%2BD3sXltlKhtrc%3D 12796218 (Pubitemid 36682312)
2. R. Tandon W.W. Fleischhacker 2005 Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment Schizophr Res. 779 145 155 10.1016/j.schres.2005.07.025 (Pubitemid 41457255)
3. E. Johnsen H.A. Jorgensen 2008 Effectiveness of second generation antipsychotics: a systematic review of randomized trials BMC Psychiatry 8 31 10.1186/1471-244X-8-31 18439263 (Pubitemid 351712549)
4. S. Leucht K. Komossa C. Rummel-Kluge 2009 A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia Am J Psychiatry 166 152 163 10.1176/appi.ajp.2008.08030368 19015230
5. J.A. Lieberman T.S. Stroup J.P. McEvoy 2005 Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med. 353 1209 1223 10.1056/NEJMoa051688 1:CAS:528:DC%2BD2MXhtVeltL%2FN 16172203 (Pubitemid 41345943)
6. P. Haddad 2005 Weight change with atypical anti-psychotics in the treatment of schizophrenia J Psychopharmacol. 19 16 27 10.1177/0269881105058378 16280334 (Pubitemid 44567855)
7. D.C. Henderson 2007 Weight gain with atypical anti-psychotics: evidence and insights J Clin Psychiatry 68 suppl.2 18 26 1:CAS:528:DC%2BD2sXhtlWjsLzK 17956152
8. I. Lipkovich L. Citrome R. Perlis 2006 Early predictors of substantial weight gain in bipolar patients treated with olanzapine J Clin Psychopharmacol. 226 316 320 10.1097/01.jcp.0000219916.88810.1c (Pubitemid 43804625)
9. T. Baptista Y. El Fakih E. Uzcategui 2008 Pharmacological management of atypical antipsychotic-induced weight gain CNS Drugs. 22 477 495 10.2165/00023210-200822060-00003 1:CAS:528:DC%2BD1cXosVCrtb4%3D 18484791 (Pubitemid 351693690)
10. N. Barak 2008 Betahistine: what's new on the agenda? Expert Opin Investig Drugs 17 795 804 10.1517/13543784.17.5.795 1:CAS:528:DC%2BD1cXlt1Shs7g%3D 18447604 (Pubitemid 351843622)
11. 3 antagonist, on olanzapine-iinduced weight gain in first-episode schizophrenia patients Int Clin Psychopharmacol. 20 101 103 10.1097/00004850-200503000-00007 15729086 (Pubitemid 40354400)
12. G.P. Reynolds M.J. Hill S.L. Kirk 2006 The 5-HT2C receptor and antipsychotic induced weight gain - mechanisms and genetics J Psychopharmacol. 20 15 18 10.1177/1359786806066040 16785265 (Pubitemid 44576653)
13. H.A. Nasrallah 2008 Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles Mol Psychiatry 13 27 35 10.1038/sj.mp.4002066 1:CAS:528:DC%2BD2sXhsVegtLrI 17848919 (Pubitemid 350275185)
14. T. Baptista J. Zarate R. Joober 2004 Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics Curr Drug Targets 5 279 299 10.2174/1389450043490514 1:CAS:528:DC%2BD2cXisFKjsL0%3D 15058313 (Pubitemid 38372313)
15. D. Gothelf B. Falk P. Singer 2002 Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine Am J Psychiatry 159 1055 11057 10.1176/appi.ajp.159.6.1055 12042200 (Pubitemid 34586957)
16. T. Baptista S. De Mendoza S. Beaulieu A. Bermudez M. Martinez 2004 The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management Metab Syndr Relat Disord. 2 290 307 10.1089/met.2004.2.290 1:CAS:528:DC%2BD2MXltlOmsL4%3D 18370698 (Pubitemid 40846902)
17. J.L. Roerig J.E. Mitchell M. de Zwaan 2005 A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors J Clin Psychopharmacol. 25 413 418 10.1097/01.jcp.0000177549.36585.29 1:CAS:528:DC%2BD2MXhtVShsLvL 16160615 (Pubitemid 41368362)
18. K.A. Graham D.O. Perkins L.J. Edwards R.C. Barrier J.A. Lieberman J.B. Harp 2005 Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis Am J Psychiatry 1162 118 123 10.1176/appi.ajp.162.1.118 (Pubitemid 40095680)
19. A. Stefanidis A.N. Verty A.M. Allen N.C. Owens M.A. Cowley B.J. Oldfield 2009 The role of thermogenesis in antipsychotic drug-induced weight gain Obesity (Silver Spring) 17 16 24 10.1038/oby.2008.468 1:CAS:528:DC%2BD1MXhtVGisg%3D%3D
20. A. Tschoner J. Engl M. Rettenbacher 2009 Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study Pharmacopsychiatry 42 29 34 10.1055/s-0028-1100425 1:STN:280:DC%2BD1M%2Fot1ansA%3D%3D 19153944
21. M. Sowell N. Mukhopadhyay P. Cavazzoni 2003 Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp J Clin Endocrinol Metab. 88 5875 5880 10.1210/jc.2002-021884 1:CAS:528:DC%2BD3sXhtVSgsrrI 14671184 (Pubitemid 38033066)
22. J. Sacher N. Mossaheb C. Spindelegger 2008 Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers Neuropsychopharmacology 33 1633 1641 10.1038/sj.npp.1301541 1:CAS:528:DC%2BD1cXlvVSrt70%3D 17712347 (Pubitemid 351684708)
23. L.J. van Nimwegen J.G. Storosum R.M. Blumer 2008 Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism J Clin Endocrinol Metab. 93 572 577 10.1210/jc.2007-1167 18029467 (Pubitemid 351240833)
24. R.R. Wu J.P. Zhao X.F. Guo 2008 Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study Am J Psychiatry 165 352 358 10.1176/appi.ajp.2007.07010079 18245179 (Pubitemid 351704491)
25. C. Roberge A.C. Carpentier M.F. Langlois 2007 Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity Am J Physiol Endocrinol Metab. 293 E1465 E1478 10.1152/ajpendo.00516.2007 1:CAS:528:DC%2BD2sXhsVGls73P 17911338 (Pubitemid 350258451)
26. B.R. Walker 2007 Glucocorticoids and cardiovascular disease Eur J Endocrinol. 157 545 559 10.1530/EJE-07-0455 1:CAS:528:DC%2BD2sXhsValu7nL 17984234 (Pubitemid 350187371)
27. B.R. Walker R. Andrew 2006 Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease Ann N Y Acad Sci. 1083 165 184 10.1196/annals.1367.012 1:CAS:528:DC%2BD2sXmslKrtA%3D%3D 17148739 (Pubitemid 44955472)
28. S.C. Langley D.A. York 1990 Effects of antiglucocorticoid RU 486 on development of obesity in obese fa/fa Zucker rats Am J Physiol. 259 R539 5544 1:CAS:528:DyaK3cXlvVCqt7o%3D 2204281
29. K.L. Beebe T. Block C. Debattista C. Blasey J.K. Belanoff 2006 The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats Behav Brain Res. 171 225 229 10.1016/j.bbr.2006.03.039 1:CAS:528:DC%2BD28Xms1Gls7s%3D 16782211 (Pubitemid 43946497)
30. C.U. Pae H.K. Lim T.S. Kim 2005 Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone Int Clin sychopharmacol. 20 173 176 10.1097/00004850-200505000-00009 (Pubitemid 40571517)
31. C.M. Beasley G.D. Tollefson P.V. Tran 1997 Safety of olanzapine J. Clin Psychiatry 58 suppl.10 13 17 1:CAS:528:DyaK2sXls1Oku78%3D 9265911
32. L. Laue M.T. Lotze G.P. Chrousos 1990 Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects J Clin Endocrinol Metab. 71 1474 1480 10.1210/jcem-71-6-1474 1:CAS:528:DyaK3MXhslyms7s%3D 2172280
33. G. Faulkner T. Cohn G. Remington 2007 Interventions to reduce weight gain in schizophrenia Schizophr Bull. 33 654 656 10.1093/schbul/sbm022 17449900 (Pubitemid 47343724)
34. M. Alvarez-Jimenez C. Gonzalez-Blanch B. Crespo-Facorro 2008 Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal CNS Drugs 22 547 562 10.2165/00023210-200822070-00002 1:CAS:528:DC%2BD1cXpt1Wrtrs%3D 18547125 (Pubitemid 351822117)
35. G. Tulipano C. Rizzetti I. Bianchi A. Fanzani P. Spano D. Cocchi 2007 Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation Neuroendocrinology 85 61 70 10.1159/000100981 1:CAS:528:DC%2BD2sXltVKjtLg%3D 17374945 (Pubitemid 46725692)
36. D.C. Henderson P.M. Copeland C.P. Borba 2006 Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis J Clin Psychiatry 67 789 797 1:CAS:528:DC%2BD28XmsVGgt7o%3D 16841629
37. S. Saddichha N. Manjunatha S. Ameen S. Ahtar 2007 Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study J Clin Psychiatry 68 1793 1798 10.4088/JCP.v68n1120 1:CAS:528:DC%2BD2sXhsVyjsbnM 18052574
38. T. Ozcanli A. Erdogan S. Ozdemir 2006 Severe liver enzyme elevations after three years of olanzapine treatment: A case report and review of olanzapine associated hepatotoxicity Prog Neuropsychopharmacol Biol Psych. 30 1163 1166 10.1016/j.pnpbp.2006.03.014 1:CAS:528:DC%2BD28XmtlGmu7o%3D (Pubitemid 43949429)